Potential Treatment
Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of approx. 10%.
Patients in the Phase 1 combination trial, for which data has been presented, have been high-risk with intermediate or poor risk cytogenetics with most patients having received three or more prior therapies including bone marrow transplant in some cases.
Could this be the best treatment? What do you think? Check disclaimer on profile